GLP-1 Agonists Show Emerging Promise for Treating Bile Acid Diarrhea

Bile acid diarrhea (BAD) is a chronic and debilitating gastrointestinal condition characterized by excessive bile acids in the colon, leading to frequent, watery stools. Current treatments, primarily bile acid sequestrants, often have limited efficacy and significant side effects, leaving many patients with unmet needs. This comprehensive review explores the potential of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) as a novel therapeutic strategy for BAD by synthesizing existing evidence.

The review highlighted that GLP-1 RAs exert multiple effects potentially beneficial for BAD, including slowing gastric emptying and reducing intestinal transit time, which could allow for greater bile acid reabsorption. Evidence suggested that GLP-1 signaling may directly or indirectly influence bile acid synthesis and enterohepatic circulation, potentially via FGF19 (Fibroblast Growth Factor 19) modulation. > The most significant finding was the identification of several mechanistic pathways by which GLP-1 RAs could reduce the frequency and severity of diarrheal episodes in patients with BAD, offering a novel therapeutic strategy. Preliminary observational data from some studies indicated a 20-30% reduction in stool frequency and improved stool consistency in patients with BAD treated with GLP-1 RAs, compared to historical controls or placebo groups. Furthermore, GLP-1 RAs were noted to modulate gut hormone release, potentially impacting bile acid secretion and absorption kinetics.